Cardiovascular Toxicity of Antitumor Drugs: Dimension of the Problem in Adult Settings

Cardiotoxicity of Non-Cardiovascular Drugs

Volumn , Issue , 2010, Pages 127-199

  Carver, Joseph R ^a   Desai, Chaitali J ^a  

^a UNIVERSITY OF THE SCIENCES   (United States)

Author keywords

Anthracyclines anchor drug of cancer chemotherapy; Antimetabolites gemcitabine related cardiovascular toxicity; Cardiotoxicity (CT) chemotherapy and anti cancer drugs; Cardiovascular toxicity of antitumor drugs in adults; Monoclonal antibodies infusion associated fever, nausea; Transmembrane receptor inhibitors tyrosine kinase inhibitors (TKI)

Indexed keywords

EID: 84858650983     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470660379.ch5     Document Type: Chapter

References (321)

1. Miller A. B., Hoogstraten B., Staquet M., et al. Reporting results of cancer treatment. Cancer 1981, 47, 207-214.
2. NCI. Cancer Treatment Evaluation Program: Common Terminology Criteria for Adverse Events v 3.0 (CTCAE), August 9, 2006. http://ctep.cancer.gov/protocol Development/electronic_applications/docs/ctcaev3.pdf, accessed January 20, 2009.
3. Fromme E. K., Eilers K. M., Mori M., et al. How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30. J. Clin. Oncol. 2004, 22, 3485-3490.
4. Von Hoff D. D., Rozencweig M., Picart M. The cardiotoxicity of anticancer drugs. Semin Oncol. 1982, 9, 23-33.
5. Shan K., Lincoff A. M., Young J. B. Anthracycline-induced cardiotoxicity. Ann. Intern. Med. 1996, 125, 47-58.
6. Killckap S., Akgul E., Aksoy S., et al. Doxorubicin-induced second degree and complete heart block. Europace 2005, 7, 227-230.
7. Wortman J. E., Lucas V. S., Schuster E., et al. Sudden death during doxorubicin administration. Cancer 1979, 44, 1588-1591.
8. O'Brian R. M., Luce J. K., Talley R. W., et al. Phase II evaluation of adriamycin in human neoplasm. Cancer 1973, 32, 1-8.
9. Steinberg J., Cohen A. J., Wasserman A. G., et al. Acute arrhythmogenicity of doxorubicin administration. Cancer 1987, 60, 1213-1218.
10. Lipshultz S. E., Colan S. D., Gelber R. D., et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. New Eng. J. Med. 1991, 324, 808-815.
11. Lipshultz S. E., Lipsitz S. R., Sallan S. E., et al. Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. J. Clin. Oncol. 2002, 20, 4517-4522.
12. Von Hoff D. D., Layard M. W., Basa P., et al. Risk factors for doxorubicin induced congestive heart failure. Ann. Intern. Med. 1979, 91, 710-717.
13. Steinherz L. J., Steinherz P. G., Tan C. T. C., et al. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. J. Am. Med. Assoc. 1991, 266, 1672-1677.
14. Zambetti M., Moliterni A., Materazzo C., et al. Long-term cardiac sequelae in operable breast cancer patients given adjuvant chemotherapy with or without doxorubicin and breast irradiation. J. Clin. Oncol. 2001, 19, 37-43.
15. Gianni L., Herman E. H., Lipshultz S. E., et al. Anthracycline cardiotoxicity: from bench to bedside. J. Clin. Oncol. 2008, 26, 3777-3787.
16. Hequet O., Le Q. H., Moulliet I., et al. Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults. J. Clin. Oncol. 2004, 22, 1864-1871.
17. Zhu W., Soonpaa M. H., Chen H., et al. Acute doxorubicin cardiotoxicity is associated with p53-inhibition of the mammalian target of rapamycin pathway. Circulation 2009, 119, 99-106.
18. Dranitsaris G., Rayson D., Vincent M., et al. The development of a predictive model to estimate cardiotoxic risk for patients with metastatic breast cancer receiving anthracycline. Breast Cancer Res. Treat. 2008, 107, 443-450.
19. Carver J. R., Shapiro C. L., Ng A., et al. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J. Clin. Oncol. 2007, 25, 3991-4008.
20. Carver J. R., Ng A., Meadows A. T., et al. Cardiovascular late effects and the ongoing care of adult cancer survivors. Dis. Manag. 2008, 11, 1-6.
21. Jain K. K., Casper E. S., Geller N. L., et al. A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer. J. Clin. Oncol. 1985, 3, 818-826.
22. Ryberg M., Nielson D., Skovsgaard T., et al. Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer. J. Clin. Oncol. 1988, 16, 3502-3508.
23. Jensen B. V., Stovsgaard T., Nielson S. L. Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. Ann. Oncol. 2002, 13, 699-709.
24. Ryberg M., Nielson D., Cortese G., et al. New insights into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients. J. Natl. Cancer Inst. 2008, 100, 1058-1067.
25. Von Dalen E. C., Michiels E. M., Caron H. M., et al. Different anthracycline derivatives for reducing cardiotoxicity in cancer patients. Cochrane Data Base Syst. Rev. 4:CD005006, 2006.
26. Batist G., Ramakrishan G., Rao C. S., et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared to conventional doxorubicin and cyclophosmphamide in a randomized, multicenter trial of metastatic breast cancer. J. Clin. Oncol. 2001, 19, 1444-1454.
27. O'brien M. E. R., Wigler N., Inbar M., et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin-HCL for the first line treatment of metastatic breast cancer. Ann. Oncol. 2004, 15, 440-449.
28. Wahlin A., Hornsten P., Hedenus M., et al. Mitoxantrone and cytarabine versus daunorubicin plus cytarabine in previously untreated patients with acute myeloid leukemia. Cancer. Chemother. Pharmacol. 1991, 28, 480-483.
29. Rowe J. M., Neuberg D., Friedenberg W., et al. Phase III study of daunorubicin vs. idarubicin vs. mitoxantrone for older adult patients (55 yrs) with acute myelogenous leukemia (AML): a study of the Eastern Cooperative Oncology Group (E3993). Blood 1998, 22:(Suppl. 1) 1284a.
30. Sessa C., Valota O., Geroni C. Ongoing phase I and II studies of novel anthracyclines. Cardiovasc. Toxicol. 2007, 7, 75-79.
31. Ravel D., Dubois V., Quinonero J., et al. Preclinical toxicity, toxicokinetics and antitumoral efficacy studies of DTS-201, a tumor-selective peptidic prodrug of doxorubicin. Clin. Cancer Res. 2008, 14, 1258-1265.
32. Delord J., Schoffski P., Brain E. et al. Results of a phase I study of DTS-201, a peptiditic prodrug of doxorubicin, in patients with solid tumors. J. Clin. Oncol. 2007, 25(abs2547).
33. Arnold D. M., Dentali F., Crowther M. A., et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann. Intern. Med. 2007, 146, 25-33.
34. Cohen S. B., Emery P., Greenwald M. W. et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arth. Rheum. 2006, 54, 2793-2806.
35. Silverman G. J., Weisman S. Rituximab therapy and autoimmune disorders: Prospects for anti-B cell therapy. Arth. Rheum. 2003, 48, 1484-1492.
36. Chesson B. D., Leonard J. P. Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. New Eng. J. Med. 2008, 359, 613-626.
37. Siano M., Lerch E., Negretti L., et al. A phase I-II study to determine the maximum tolerated infusion rate of rituximab with special emphasis on monitoring the effect of rituximab on cardiac function. Clin. Cancer Res. 2008, 14, 7935-7939.
38. Pfreundschuh M., Trumper L., Osterborg A., et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomized controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006, 7, 379-391.
39. Coiffier B., Lepage E., Briere J., et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. New Eng. J. Med. 2002, 346, 235-242.
40. Armitage J. D., Montero C., Benner A., et al. Acute coronary syndromes complicating the first infusion of rituximab. Clin. Lymphoma Myeloma 2008, 8, 2553-2555.
41. Cervera Grau J. M., Galiana G. E., Candela A. B., et al. Complete atrioventricular block induced by rituximab in monotherapy in an aged patient with non-Hodgkin's diffuse large B-cell lymphoma. Clin. Transl. Oncol. 2008, 10, 298-299.
42. Butts, C. A., Bodkin D., Middleman E. L., et al. Randomized phase II study of gemcitabine plus cisplatin or carboplatin, with or without cetuximab, as first-line therapy for patients with advanced or metastatic non-small cell lung cancer. J. Clin. Oncol. 2007, 25, 5777-5784.
43. Safran H., Suntharalingham M., Dipetrillo., et al. Cetuximab with concurrent chemoradiation for esophagogastric cancer: assessment of toxicity. Int. J. Rad. Oncol. 2008, 70, 391-395.
44. Bertolini F., Chiara S., Bengala C., et al. Neoadjuvant treatment with single-agent cetuximab followed by 5-FU, cetuximab, and pelvic radiotherapy: a phase II study in locally advanced rectal cancer. Int. J. Rad. Oncol. 2009, 73, 466-472.
45. Pryer D. I., Porceddu S. V., Birmeister B. H., et al. Enhanced toxicity with concurrent cetuximab and radiotherapy in head and neck cancer. Radiother. Oncol. 2009, 90, 172-176.
46. Tol J., Koopman M., Cats A., et al. Chemotherapy, bevacimab, and cetuximab in metastatic colorectal cancer. New Eng. J. Med. 2009, 360, 563-572.
47. Saltz L. B., Meropol N. J., Loehrer P. J., et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol. 2004, 22, 1201-1208.
48. Lenihan D. J., Alencar A. J., Yang D., et al. Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sezary syndrome. Blood 2004, 104, 655-658.
49. Keating M. J., Cazin B., Coutre S., et al. Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. J. Clin. Oncol. 2002, 20, 205-213.
50. Ferrajoli A., O'Brien S. M., Cortes J. E., et al. Phase II study of alemtuzumab in chronic lymphoproliferative disorders. Cancer 2003, 98, 773-778, 2003.
51. Lundin A., Osterborg A., Brittinger G., et al. Campath-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. J. Clin. Oncol. 1998, 16, 3257-3263.
52. Damaj G., Rubio M. T., Audard V., Hermine O. Severe cardiac toxicity after monoclonal antibody therapy. Eur. J. Haematol. 2002, 98, 324.
53. Lundin J., Kennedy B., Dearden C., et al. No cardiac toxicity associated with alemtuzumab therapy for mycosis fungoides/Sezary syndrome. Blood 2005, 105, 4148- 4149.
54. Bernengo M. G., Quaglino P., Comessatti A., et al. Low-dose intermittent alemtuzumab in the treatment of Sezary syndrome: clinical and immunologic findings in 14 patients. Haematologica 2007, 92, 784-794.
55. Hillmen P., Skotnicki A. B., Robak T., et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J. Clin. Oncol. 2007, 25, 5616-5623.
56. Alinari I., Lapalombella R., Andritsos L., et al. Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia, Oncogene 2007, 26, 3644-3653.
57. Woodside K. J., Lick S. D. Alemtuzumab (Campath 1h) as successful salvage therapy for recurrent steroid -resistant heart transplant rejection. J. Heart Lung Transp. 2007, 26, 750-752.
58. Slamon D. J., Clark G. M., Wong S. G., et al. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235, 177-182.
59. Slamon D. J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New Eng. J. Med. 2001, 344, 783-792.
60. Seidman A., Hudis C., Pierri M. K., et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J. Clin. Oncol. 2002, 20, 1215-1221.
61. Seidman A. D., Berry D., Cirrincione C., et al: Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J. Clin. Oncol. 2008, 26, 1642-1649.
62. Marty M., Cognetti F., Maraninchi D., et al. Efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: Results of a randomized phase II-Trial by the M77001 Study Group. J. Clin. Oncol. 2005, 23, 4265-4274.
63. Robert N., Leyland-Jones B., Asmar L., et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J. Clin. Oncol. 2006, 24, 2786-2792.
64. Pegram M., Forbes J., Pienkowski T., et al. BCIRG 007: First overall survival analysis of randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin as first line therapy in HER2 amplified metastatic breast cancer (MBC). J. Clin. Oncol. 2007, 25, 18S, (abst 1008).
65. Burstein H., Lyndsay N., Harris P., et al. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: Multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J. Clin. Oncol. 2003, 21, 2889-2895.
66. O'Shaughnessy J., Vukelja S. J., Marsland T., et al. Phase II trial of gemcitabine plus trastuzumab in metastatic breast cancer patients previously treated with chemotherapy: preliminary results. Clin. Breast Cancer 2002, 3 (Suppl 1), 17-20.
67. Wardley A., Anton-Torres A., Pivot X., et al. Evaluation of trastuzumab, docetaxel and capecitabine as first line therapy for HER2-positive locally advanced or metastatic breast cancer. Breast Cancer Res. Treat. 2007, 106 (Suppl 1), S33, [abstract 309].
68. Guarneri V., Lenihan D. J., Valese V., et al. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. J. Clin. Oncol. 2006, 24, 4107-4115.
69. Untch M., Eidtmann H., du Bois A., et al. Cardiac safety of trastuzumab in combination with epirubicin and cyclophosphamide in women with metastatic breast cancer: Results of a phase I trial. Eur. J. Cancer 2004, 40, 988-997.
70. Tan-Chiu E., Yothers G., Romond E., et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J. Clin. Oncol. 2005, 23, 7811-7819.
71. Perez E., Suman V., Davidson N., et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J. Clin. Oncol. 2008, 26, 1231-1238.
72. Slamon D., Eiermann W., Robert N., et al. BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2- neu positive early breast cancer patients. 29th Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, December 14-17, 2006 (abstr. 52).
73. Joensuu H., Kellokumpu-Lehtinen P. L., Bono P., et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. New Engl. J. Med. 2006, 354, 809-820.
74. Suter T. M., Procter M., van Veldhuisen D. J., et al. Trastuzumab-associated cardiac adverse effects in the Herceptin adjuvant trial. J. Clin. Oncol. 2007, 25, 3859-3865.
75. Rayson D., Richel D., Chia S., et al. Anthracycline-trastuzumab regimens for HER2/ neu-overexpressing breast cancer: current experience and future strategies. Ann. Oncol. 2008, 19, 1530-1539.
76. Dang C., Fornier M., Sugarman S., et al. The safety of dose-dense doxorubicin and cyclphosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressing/ amplified breast cancer. J. Clin. Oncol. 2008, 26, 1216-1222.
77. Gomez H. L., Doval D. C., Chavez M. A., et al. Efficacy and safety of lapatinib as firstline therapy for ERB2-amplified locally advanced or metastatic breast cancer. J. Clin. Oncol. 2008, 26, 2999-3005.
78. Perez E. A., Koehler M., Byrne J., et al. Cardiac safety of lapatinib: Pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clinic Proc. 2008, 83, 679-686.
79. Harrington K., El-Hariry I. A., Holford C. A., et al. Phase I study of lapatinib in combination with chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck. J. Clin. Oncol. 2009, 27, 1100-1107.
80. Arriaga Y., Becerra C.R. Adverse effects of bevacizumab and their management in solid tumors. Supp. Cancer Ther. 2006, 3, 247-250.
81. Genentech: Avastin (bevacizumab) prescribing information. San Francisco, CA, 2008, date last accessed 22 February 2009.
82. Zhu X., Wu S., Dahut W., et al. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am. J. Kidney Dis. 2007, 49, 186-193.
83. Kabbinavar F., Hurwitz H., Fehrenbacher L., et al. Phase II randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J. Clin. Oncol. 2003, 21, 60-65.
84. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. New Eng. J. Med. 2004, 350, 2335-2342.
85. Scappaticci F. A., Skillings J. R., Holden S. N., et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J. Natl. Cancer Inst. 2007, 99, 1232-1239.
86. Saltz L. B., Clarke S., Diaz-Rubio E., et al. Bevacizumab in combination with oxaliplatin- based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J. Clin. Oncol. 2008, 26, 2013-2019.
87. Purdie D. M., Berlin J. D., Flynn P. J., et al. The safety of long-term bevacizumab use: results from the BRITE observational cohort study (abs) J. Clin. Oncol. 2008, 26, 4103.
88. Richardson S., Dickler M., Dang C., et al, Tolerance of bevacizumab in an older patient population: the Memorial Sloan-Kettering Cancer Center experience. J. Clin. Oncol., 2008 ASCO Annual Meeting Proceedings 26 (abstr 519).
89. Sereno M., Brunello A., Chiappori A., et al. Cardiac toxicity: old and new issues in anti-cancer drugs. Clin. Transl. Oncol. 2008, 10, 35-46.
90. Nalluri S. R., Chu D., Kereszetes R., et al. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. J. Am. Med. Assoc. 2008, 300, 2277-2285.
91. Karp J. E., Gojo I., Pili R., et al. Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias. Clin. Cancer Res. 2004, 10, 3577-3585.
92. Miller K. D., Chapp L. I., Hulmer F. A., et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J. Clin. Oncol. 2005, 23, 792-799.
93. D'Adamo D. R., Anderson S. E., Albritton K., et al. Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. J. Clin. Oncol. 2005, 23, 7135-7142.
94. Nguyen Q. D., Shah S. M., Hafiz G., et al. A phase I trial of an IV-administered vascular endothelium growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2006, 113, 1522e1-e14.
95. Crino L., Mosconi A. M., Scagliotti G., et al. Gemcitabine as second-line treatment for advanced non-small-cell lung cancer: a phase II trial. J. Clin. Oncol. 1999, 17, 2081-2086.
96. Dent S., Messersmith H., Trudeau M. Gemcitabine in the management of metastatic breast cancer: a systematic review. Breast Cancer Res.Treat. 2008, 108, 319-331.
97. Sauer-Heilborn A., Kath R., Schneider C. P., et al. Severe non haematological toxicity after treatment with gencitabine. J. Cancer Res. Clin. Oncol. 1999, 125, 637-640.
98. Azzoli C. G., Miller V. A., Ng K. K., et al. Gemcitabine-induced peripheral edema: report on 15 cases and review of the literature.Am. J. Clin.Oncol. 2003, 26, 247-251.
99. Storniolo A. M., Allerheiligen S. R., Pearce H. L. Preclinical, pharmacologic and phase I studies of gemcitabine. Semin. Oncol. 1997, 24 (Suppl 2), S72-S77.
100. Santini D., Tonini G., Abbate A., et al. Gemcitabine-induced atrial fibrillation: a hitherto unreported manifestation of drug toxicity. Ann. Oncol. 2000, 11, 479-481.
101. Ferrari D., Carbone C., Codeca C., et al. Gemcitabine and atrial fibrillation: a rare manifestation of chemotherapy toxicity. Anticancer Drugs 2006, 17, 359-361.
102. Tavil Y., Arslan K., Sen N., et al. Atrial fibrillation induced by gemcitabine treatment in a 65 year old man. Onkologic 2007, 30, 253-255.
103. Ozturk B., Tacoy G., Coskun U., et al. Gemcitabine-induced acute coronary syndrome: a case report. Med. Princ. Prac. 2009, 18, 76-80.
104. Bdair F., Graham S. P., Smith P., et al. Gemcitabine and acute myocardial infarction: a case report. Angiology 2006, 57, 367-371.
105. Vogl D., Glatstein E., Carver J., et al. Gemcitabine-induced pericardial effusion and tamponade after unblocked cardiac irradiation. Leuk. Lymph. 2005, 46, 1313-1320.
106. Hermans C., Straetmans N., Michaux J. L., et al. Pericarditis induced by high dose cytosine arabinoside chemotherapy. Ann. Hematol. 1997, 75, 55-57.
107. Gahler A., Hitz F., Hess U., et al. Acute pericarditis with pleural effusion complicating cytarabine chemotherapy. Onkologie 2003, 26, 348-350.
108. Vaickus L., Letendre L. Pericarditis induced by high-dose cytarabine therapy. Arch. Intern. Med. 1984, 144, 1868.
109. Reykdal S., Sham R., Kouides P. Cytarabine-induced pericarditis: a case report and review of the literature of the cardiopulmonary complications of cytarabine therapy. Leuk. Res. 1995, 19, 141-144.
110. Stamatopoulos K., Kanellopoulou G., Vaiopoulos G., et al. Evidence for sinoatrial blockade associated with high dose cytarabine therapy. Leuk. Res. 1998, 22, 759-761.
111. Cil T., Kaplan V. Cytosine-arabinase induced bradycardia in a patient with non- Hodgin's lymphoma: a case report. Leuk. Lymph. 2007, 48, 1247-1249.
112. Conrad M. E. Cytarabine and cardiac failure. Am. J. Hemat. 1992, 41, 143.
113. Diasio R. B., Harris B. E. Clinical pharmacology of 5-fluorouracil. Clin. Pharmacokinet. 1989, 16, 1c (4), 215-237.
114. Diasio R. B., Beavers T. L., Carpenter J. T. Familial deficiency of dihydropyrimidine dehydrogenase: biochemical basis for familial pyrimidinemia and severe 5- fluorouracil- induced toxicity. J. Clin. Invest. 1988, 81, 47-51.
115. Schwab M., Zanger U. M., Marx C., et al. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: A prospective clinical trial by the German 5-FU toxicity study group. J. Clin. Oncol. 2008, 26, 2131-2138.
116. Labianca R., Beretta G., Glenici M., et al. Cardiac toxicity of 5-fluorouracil: a study of 1,083 patients. Tumori 1982, 68, 505-510.
117. Keefe D. L., Roistacher N., Pierri M. K. Clinical cardiotoxicity of 5-fluorouracil. J. Clin. Pharmacol. 1993, 33, 1060-1070.
118. Boroker T. R., O'Connell M. J., Wieand H. S., et al. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J. Clin. Oncol. 1994, 12, 14-20.
119. The Meta Analysis Group in Cancer. Toxicity of fluorouracil in patients with advanced colorectal cancer: Effect of administration schedule and prognostic factors. J. Clin. Oncol. 1998, 16, 3537-3541.
120. Saltz L. B., Cox J. V., Blanke C., et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. New Eng. J. Med. 2000, 343, 905-914.
121. Sloan J. A., Goldberg R. M., Sargent D. J., et al. Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer. J. Clin. Oncol. 2002, 20, 1491-1498.
122. de Gramant A., Bosser J. F., Milan C., et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J. Clin. Oncol. 1997, 15, 808-815.
123. Patel K., Anthoney D. A., Crelin A. M., et al. Weekly 5-fluorouracil and leucovorin: Achieving lower toxicity with higher dose-intensity in adjuvant chemotherapy after colorectal cancer resection. Ann. Oncol. 2004, 15, 568-573.
124. Tsibiribi P., Descotes J., Lombard-Bohas C., et al. Cardiotoxicity of 5-fluorouracil in 1,350 Bull Cancer 2006, 93, E27-30.
125. Kuropkat C., Griem K., Clark J., et al. Severe cardiotoxicity during 5-fluorouracil chemotherapy: A case and literature report. Am. J. Clin. Oncol. 1999, 22, 466.
126. Sasson Z., Morgan C. D., Wang B., et al. 5-fluorouracil related toxic myocarditis: Case reports and pathological confirmation. Can. J. Cardiol. 1994, 10, 861-864.
127. Brillet G., Deray G., Baumelou A., et al. Acute cardiac and renal failure after 5-FU and cisplatin treatment. Nephron 1991, 59, 667-668.
128. Bertino J., Gameli E., Milano G. 5-fluorouracil drug management: pharmacokinetics and pharmacogenomics meeting summary. Clin. Colorectal Cancer 2007, 6(6), 407-422.
129. Ezzeldin H. H., Diasio R. B. Predicting fluorouracil toxicity: Can we finally do it? J. Clin. Oncol. 2008, 26, 2080-2082.
130. Papadopulos C. A., Wilson H. Capecitabine-associated coronary vasospasm: A case report. Emerg. Med. 2008, 25, 307-309.
131. To A. C., Looi K. L., Danmianovich D., et al. A case of cardiogenic shock caused by capecitabine treatment. Nature Clin. Prac. Cardiovasc. Med. 2008, 5, 725-729.
132. Dalzell J. R., Samuel L. M. The spectrum of 5-fluorouracil cardiotoxicity. Anticancer Drugs 2009, 20, 79-80.
133. Manojiovic N., Babic D., Stojanovic S., et al. Capecitabine cardiotoxicity-case reports and literature review. Hepato-gastroenterology 2006, 55, 1249-56.
134. Scott P. A., Ferchow L., Hobson A., et al. Coronary spasm induced by capecitabine mimics ST elevation myocardial infarction. Emerg. Med. J. 2008, 25, 699-700.
135. Goldsmith Y. B., Roistacher N., Baum M. S. Capecitabine-induced coronary vasospasm. J. Clin. Oncol. 2008, 26, 3802-3804.
136. Personnel data on file
137. Shah M., Binkley P., Chan K., et al. Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors. Clin. Cancer Res. 2006, 12, 3997-4003.
138. Pierkarrz R. L., Frye R., Wright J. J., et al. Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma. Clin. Cancer Res. 2006, 80, 3762-3772.
139. Santos G. W., Sensenbrenner L. L., Burke P. J., et al. Marrow transplantation in man following cyclophosphamide. Transp. Proc. 1971, 3, 400-404.
140. Gottdiener J. S., Appelbaum F. R., Ferrnac V. J., et al. Cardiotoxicity associated with high dose cyclophosphamide therapy. Arch. Intern. Med. 1981, 141, 758-763.
141. Goldberg M. A., Antin J. H., Guinan E. C., et al. Cyclophosphamide cardiotoxicity: An analysis of dosing as a risk factor. Blood, 1986, 68, 1114-1118.
142. Zver S., Zadnik V., Bunc M., et al. Cardiac toxicity of high dose cyclophosphamide in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation. Int. J. Hemat. 2007, 85, 408-414.
143. Wang X., Zang J., Xu T. Cyclophosphamide-evoked heart failure involves cosuppression of cytoplasmic thioredoxin reductase activity and non-protein free thiol level. Eur. J. Heart Failure 2009, 11, 154-162.
144. Klastersky J. Side-effects of ifosfamide Oncology 2003, 65(Suppl. 2), 7-10.
145. Kandylis K., Vassilomanolakis M., Tsoussis S., Efremidis A.P. Ifosfamide cardiotoxicity in humans. Cancer Chemother. Pharmacol. 1989, 24, 395-396.
146. Elias A. D., Eder J. P., Shea T., et al. High-dose ifosfamide with mesna uroprotection: a phase I study. J. Clin. Oncol. 1990, 8, 170-178.
147. Quezado Z. M., Wilson W. H., Cunnion R. E., et al. High-dose ifosfamide is associated with severe, reversible cardiac dysfunction. Ann. Intern. Med. 1993, 118, 31-36.
148. Hait W. N., Rubin E., Alli E., et al. Tubulin targeting agents. Update Cancer Therap. 2007, 2, 1-18.
149. Mandel E., Lewinski U., Djaldetti M. Vincristine-induced myocardial infarction. Cancer 1975, 36, 1979-1982.
150. Lejonc J. L., Vernant J. P., Macquin J., et al. Myocardial infarction following vinblastine treatment. Lancet 1980, 2, 692.
151. Yancey R. S., Talpaz M. Vindesine associated angina and ECG changes. Cancer Treat. Rep. 1982, 66, 587-89.
152. Lapeyre-Mestre M., Gregoire N., Bugat R., et al. Vinorelbine-related cardiac events: a meta-analysis of randomized clinical trials. Fund. Clin. Pharmacol. 2004, 18, 97-105.
153. Toi M., Saeki T., Aogi K., et al. Late phase II clinical study of vinorelbine monotherapy in advanced or recurrent breast cancer previously treated with anthracyclines and taxanes. Jpn. J. Clin. Oncol. 2005, 35, 310-315.
154. Papaldo P., Fabi A., Ferretti G., et al. A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER 2 expression: changing the natural history of HER 2-positive disease. Ann. Oncol. 2006, 17, 630-636.
155. Chan A. A review of the use of trastuzumab (Herceptin) plus vinorelbine in metastatic breast cancer. Ann. Oncol. 2007, 18, 1152-1158.
156. Bennouna J., Delord J. P., Campone M., Pinel M. C. Vinflunine: a new microtubule inhibitor agent. Clin. Cancer Res. 2008, 14, 1625-1632.
157. Chan S., Friedrichs K., Noel D., et al. Prospective randomized trial of doxetaxel versus doxorubicin in patients with metastatic breast cancer. J. Clin. Oncol. 1999, 17, 2341-2354.
158. Sledge G., Newberg D., Bernardo P., et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line therapy for metastatic breast cancer: An Intergroup trial (E1193). J. Clin. Oncol. 2003, 21, 588-592.
159. Rowinsky E. K., McGuire W. P., Guaerlieri T., et al. Cardiac disturbances during the administration of paclitaxel. J. Clin. Oncol. 2000, 22, 1029-1033.
160. Giordano S. H., Booser D. J., Murray J. L., et al. A detailed evaluation of cardiac toxicity: A phase II study of doxorubicin and one-or three-hour infusion of paclitaxel in patients with metastatic breast cancer. Clin. Cancer Res. 2002, 8, 3360-3368.
161. Gianni L., Basselga J., Eiermann W., et al. Feasibility and tolerability of sequential doxorubicin-paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects of tumor response as pre-op therapy. Clin. Cancer Res. 2005, 11, 8715-8721.
162. Biganzoli L., Licitra S., Moretti E., et al. Taxanes in the elderly: can we gain as much and be less toxic? Crit. Rev. Oncol./Hematol. 2008, 70(3), 262-271.
163. Bellot R., Robert J., Dieras V., et al. Taxotere does not change the pharmacokinetic profile of doxorubicin and doxorubicinol. Proc. Am. Soc. Clin. Oncol. 1998, 12, 221A (Abs 853).
164. Gradishar W. J., Tjulandin S., Davidson N., et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared to polyehtethylated castor-oil based paclitaxel in women with breast cancer. J. Clin. Oncol. 2005, 23, 7794-7863.
165. Trimble E. L., Adami J. D., Vena D., et al. Paclitaxel for platinum-refractory ovarian cancer: Results from the first 1000 patients registered to the National Cancer Institute Treatment Referral Center 9103. J. Clin. Oncol. 1993, 11, 2405-2410.
166. Sevelda P., Mayerhofer K., Obermair A., et al. Thrombosis with paclitaxel. Lancet 1994, 343, 727.
167. Dieras V., Limentani S., Romieu G., et al. Phase II multicenter study of larotaxel (XRP9881) a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapy. Ann. Oncol. 2008, 19, 1255-1260.
168. Chu D., Lu J. Novel therapies on breast cancer: what is new from ASCO 2008. J. Hematol. Oncol. 2008, 1(16), 1-16.
169. Lee J. J., Swain S. M. The epothilones: translating from the laboratory to the clinic. Clin. Cancer Res. 2008, 14, 1618-1624.
170. Cortes J., Baselga J. Targeting the microtubules in breast cancer beyond taxanes: the epothilones. Oncologist 2007, 12, 271-280.
171. Lechleider R. J., Kaminskas E., Jiang X., et al. Ixabepitone in combination with capecitabine and as monotherapy for the treatment of advanced breast cancer refractory to previous chemotherapies. Clin. Cancer Res. 2008, 14, 4378-4384.
172. Rivera E., Lee J., Davies A. Clinical development of ixabepilone and other epithilones in patients with advanced solid tumors. Oncologist 2008, 13, 1207-1223.
173. Barlogie B., Desikan R., Eddlemon P., et al. Extended survival in advanced and refractory multiple myeloma after single agent thalidomide: identification of prognostic factors in a phase II study of 169 patients. Blood 2001, 98, 492-494.
174. Zangari M., Analssie E., Barlogie B., et al. Increased risk of deep-venin thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 2001, 98, 1614-1615.
175. Zangari M., Siegel E., Barlogie B., et al. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood 2002, 100, 1168-1171.
176. Osman K., Comenzo R., Rajkumar S. V. Deep vein thrombosis and thalidomide therapy for multiple myeloma. New Eng. J. Med. 2001, 344, 1951-1952.
177. Urbauer E., Kaufmann H., Nosslinger T., et al. Thromboembolic events during treatment with thalidomide. Blood 2002, 99, 4247-4248.
178. Desai A. A., Vogelzang N. J., Rini B., et al. A phase II trial of weekly intravenous gemcitabine (G) with prolonged continuous infusion 5-fluorouracil (F) and oral thalidomide (T) in patients with metastatic renal cell cancer. J. Clin. Oncol. 2008, 20, 2448 (abstract).
179. Singhal S., Mehta J. Thalidomide in cancer: potential uses and limitations. BioDrugs 2001, 15, 163-72.
180. Dimopoulos M. A., Eleutherakis V. Adverse effects of thalidomide administration in patients with neoplastic disease. Am. J. Med. 2004, 117, 508-515.
181. Zervas K., Dimopoulos A., Hatzkharissi A., et al. Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxyl): a phase II multicenter study. Ann. Oncol. 2004, 15, 134-138.
182. Gordinier M., Dizon D. Dyspnea during thalidomide treatment for advanced ovarian cancer. Ann. Pharmacother. 2005, 39, 962-965.
183. Raza A., Meyer P., Dutt D., et al. Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood 2001, 98, 958-965, 2001.
184. Younis T. H. Reversible pulmonary hypertension and thalidomide therapy for multiple myeloma. Brit. J. Haematol. 2003, 121, 191-192.
185. Rajkumar S., Jacobus S., Callender N., et al. Phase III trial of lenalidomide plus highdose dexamethasone versus lenalidomide plus low-dose dexamethasone plus lowdose dexamethasone in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group. J. Clin. Oncol. 2007, 25, 447S, (abstract 8025).
186. Richardson R. G., Blood E., Mitsiades C. S., et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed and refractory multiple myeloma. Blood 2006, 108, 3458-3464.
187. Chanan-Khan A. A., Cheson B. D. Lenalidomide for the treatment of B-cell malignancies. J. Clin. Oncol. 2008, 26, 1544-1552.
188. Schey S. A., Fields P., Bartlett J. B., et al. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J. Clin. Oncol. 2004, 22, 3269-3276.
189. Druker B. J., Guilhot F., O'brien S. G., et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. New Eng. J. Med. 2006, 355, 2408-2417.
190. Cohen M. H., Williams G., Johnson J. R., et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin. Cancer Res. 2002, 8, 935-942.
191. Kerkela R. Grazette L., Yacobi R., et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat. Med. 2006, 12, 908-916.
192. Beccia M., Cannella L., Frustaci A., et al. Cardiac events in imatinib mesylate-treated chronic myeloid leukemia patients: a single institution experience. Leuk. Res. 2008, 32, 835-836.
193. Park Y. H., Park H. J., Kim B. S., et al. BNP as a marker of the heart failure in the treatment of imatinib mesylate. Cancer Lett. 2006, 243, 16-22.
194. Atallah E., Durand J. B., Kantarjian H., et al. Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood 2007, 110, 1233-1237.
195. Lloyd-Jones D. M., Larson M. G., Leip E. P., et al. Life-time risk for developing congestive heart failure: the Framingham heart study. Circulation 2002, 106, 3068- 3072.
196. Ribeiro A. L., Soriano-Marcolino M., Bittencourt H. N. S., et al. An evaluation of the cardiotoxicity of imatinib mesylate. Leuk. Res. 2008, 32, 1809-1814.
197. Motzer R. J., Rini B. I., Bukowski R. M., et al. Sunitinib in patients with metastatic renal cell carcinoma. J. Am. Med. Assoc. 2006, 295, 2516-2524.
198. Pfizer: SUTENT (sunitinib malate) prescribing information. New York, 2008 (date last accessed, 21 February 2009).
199. Motzer R. J., Hutson T. E., Tomczak P., et al. Sunitinib versus interferon alpha in metastatic renal cell carcinoma. New Eng. J. Med. 2007, 356, 115-124.
200. Chu T. F., Rupnick M. A., Kerkela R., et al. Cardiotoxicity associated with the tyrosine kinase inhibitor sunitinib. Lancet 2007, 370, 2011-2019.
201. Telli M. L., Witteles R. M., Fisher G. A., et al. Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. Ann. Oncol. 2008, 19, 1613-1618.
202. Khakoo A. Y., Kassiotis C. M., Tannir N., et al. Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor. Cancer 2008, 112, 2500-2508.
203. Chen M. H., Kerkela R., Force T. Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics. Circulation 2008, 117, 84-95.
204. Escudier B., Eisen T., Stadler W. M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. New Engl. J. Med. 2007, 356, 125-134.
205. WuS., Chen J. J., Kudelka A., et al. Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol. 2008, 9, 117-123.
206. Mego M., Reckova J., Obertiva Z., et al. Increased cardiotoxicity of sorafenib in sunitinib-pretreated patients with metastatic renal cell carcinoma. Ann. Oncol. 2007, 18, 1906-1907.
207. Schmidinger M., Zielinski C. C., Vogl U. M., et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 2008, 26, 5204-5212.
208. Rosen L. S., Kurzrock R., Mulay M., et al. Safety, pharmacokinetics and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. J. Clin. Oncol. 2007, 25, 2369-2376.
209. Monk B. J., Sill M. W., Burger R. A. et al. Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J. Clin. Oncol. 2009, 27, 1069-1074.
210. Cohen M. H., Johnson J. R., Chen Y. F., et al. FDA drug approval summary: erlotinib (Tarceva) tablets. Oncologist 2005, 10, 461-466.
211. Gatzemeier U., Pluzanska A., Szczesna A., et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small cell lung cancer: the tarceva lung cancer investigation trial. J. Clin. Oncol. 2007, 25, 1545-1552.
212. Philip P. A., Mahoney M. R., Allmer C., et al. Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J. Clin. Oncol. 2005, 23, 6657-6663.
213. Cohen M. H., Williams G. A., Sridhara R., et al. FDA drug approval summary: gefitinib (ZD1839) (Iressa)) tablets. Oncologist 2003, 8, 303-306.
214. Canil C. M., Moore M. J., Winquist E., et al. Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group. J. Clin. Oncol. 2005, 23, 455-460.
215. Kelly K., Chansky K., Gasper L. E., et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small cell lung cancer-SWOG S0023. J. Clin. Oncol. 2008, 26, 2450-2456.
216. Jiang H. Overview of gefitinob in non-small cell lung cancer: an Asian perspective. Jpn. J. Clin. Oncol. 2009, 39, 137-150.
217. Inoue A., Kobayashi K., Usai K., et al. First-line gefitinib for patients with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J. Clin. Oncol. 2009, 27, 1394-1400.
218. Duvic M., Martin A. G., Kim Y., et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous t-cell lymphoma. Arch. Dermatol. 2001, 137, 581-593.
219. Duvic M., Hyme K., Heald P., et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J. Clin. Oncol. 2001, 19, 2456-2471.
220. Straus D. J., Duvic M., Kuzel T., et al. Results of a phase II trial of oral bexarotene (Targretin) combined with interferon alfa-2b (Intron-A) for patients with cutaneous t-cell lymphoma. Cancer 2007, 109, 1799-1803, 2007.
221. Jagannath S., Barlogie B., Berenson J. R., et al. SUMMIT/CREST Investigators: Bortezomib in recurrent and/or refractory multiple myeloma: Initial clinical experience in patients with impaired renal function. Cancer 2005, 103, 1195-1200.
222. Richardson P. G., Sonneveld P., Schuster M. W., et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. New Engl. J. Med. 2005, 352, 2487- 2498.
223. Lee J., Suh C., Kang H. J., et al. Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma. Ann. Oncol. 2008, 19, 2079-2083.
224. Palumbo A., Gay F., Bringhen S., et al. Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma. Ann. Oncol. 2008, 19, 1160-1165.
225. Hachihanefioglu A., Tarkun P. Acute severe cardiac failure in a myeloma patient due to proteasome inhibitor bortezomib. Int. J. Hematol. 2008, 88, 219-222.
226. Voortman J., Smit E. F., Honeywell R., et al. A parallel dose-escalation study of weekly and twice-weekly bortezomib in combination with gemcitabine and cisplatin in the first-line treatment of patients with advanced solid tumors. Clin. Cancer Res. 2007, 13, 3642-3651.
227. Suvannasankha A., Smith G. G., Julier B. E., et al. Weekly bortezomib/methylprednisolone is effective and well tolerated in relapsed multiple myeloma. Clin. Lymph. Myeloma 2006, 7, 131-134.
228. Orciuolo E., Buda G., Cecconi N., et al. Unexpected cardiotoxicity in haematological bortezomib treated patients. Br. J. Haematol. 2007, 138, 396-397.
229. Berenson J. R., Matous J., Swift R. A., et al. A phase I/II study of arsenic trioxide/ bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma. Clin. Cancer Res. 2007, 13, 1762-1768.
230. Orlowski R. Z., Kuhn D. J. Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin. Cancer Res. 2008, 14, 1649-1657.
231. Hansen S. W., Olsen N., Rossing N., Roth M. Vascular toxicity and the mechanism underlying Raynaud's phenomenon in patients treated with cisplatin, vinblastine and bleomycin. Ann. Oncol. 1990, 1, 289-292.
232. Pretner-Oblak J., Zaletel M., Jagodic M., et al. Thrombosis of internal carotid artery after cisplatin-based chemotherapy. Eur. Neurol. 2007, 57, 109-110.
233. King M., Fernando I. Vascular toxicity associated with cisplatin. Clin. Oncol. 2003, 13, 36-37.
234. Icli F., Karaoguz H., Dincol D., et al. Severe vascular toxicity associated with cisplatin-based chemotherapy. Cancer, 1993, 72, 587-593.
235. Vogelzang N. H., et al. Hypomagnesemia, renal dysfunction, and Raynaud's phenomenon in patients treated with cisplatin, vinblastine, and bleomycin. Cancer 1985, 56, 2765-2770.
236. Nuver J., Smit A. J., Van der Meer J., et al. Acute chemotherapy-induced cardiovascular changes in patients with testicular cancer. J. Clin. Oncol. 2005, 23, 9130-9137.
237. The International Adjuvant Lung Cancer Trial Collaborative Group: cisplatin-based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. New Engl. J. Med. 2004, 350, 351-360.
238. Winton T., Livingston R., Johnson D., et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. New Engl. J. Med. 2005, 352, 2589-2597.
239. Pignon J. P., Tribodet H., Scagliotti G. V., et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J. Clin. Oncol. 2008, 26, 3552-3559.
240. Hashini L. A., Khayly M. F., Salem P. A. Supraventricular tachycardia. A probable complication of platinum treatment. Oncology 1984, 41, 174-175.
241. Tassinari D., Sartori S. M., Rudi G., et al. Cardiac arrhythmias after cisplatin infusion: three case reports and a review of the literature. Ann. Oncol. 1997, 8, 1263-1267.
242. Altundag O., Celik I., Kars A. Recurrent asymptomatic bradycardia episodes after cisplatin infusion. Ann. Pharmacother. 2001, 35, 641-642.
243. Menard O., Martinet Y., Lamy P. Cisplatin-induced atrial fibrillation. J. Clin. Oncol. 1991, 9, 192-193.
244. Yavas O., Aytemis K., Celik I. The prevalence of silent arrhythmias in patients receiving cisplatin-based chemotherapy. Turk. J. Cancer 2008, 38, 12-15.
245. González-Martín A. J., Calvo E., Bover I., et al. Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: A GEICO (Grupo Espanol de Investigacion en Cancer de Ovario) study. Ann. Oncol. 2005, 16, 749-755.
246. Ibrahim A., Hirschfeld S., Cohen M. H., et al. FDA drug approval summaries: oxaliplatin. Oncologist 2004, 9, 8-12.
247. Huddart R. A., Norman A., Shahidi M., et al. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J. Clin. Oncol. 2003, 21, 1513-1523.
248. Raghavan D., Cox K., Childs A., et al. Hypercholesterolemia after chemotherapy for testis cancer. J. Clin. Oncol. 1992, 10, 1386-1389.
249. MeinardiM. T., Gietema J. A., van der GraafW. T., et al. Cardiovascular morbidity in long-term survivors ofmetastatic testicular cancer. J. Clin.Oncol. 2000, 18, 1725-1732.
250. Vaughn D. J., Palmer S. C., Carver J. R. et al. Cardiovascular risk in long-term survivors of testicular cancer. Cancer 2008, 112, 1949-1953.
251. Sternberg C. N., Petrylak D., Witjes J., et al. Satraplatin (S) demonstrates significant clinical benefits for the treatment of patients with HRPC: results of a randomized phase III trial. J. Clin. Oncol. 2007, 25, 18S (abstract 5017).
252. Choy H., Park C., Yao M. Current status and future prospect for satraplatin: an oral platinum analogue. Clin. Cancer Res. 2008, 4, 1618-1623.
253. Dizon D. S., Maluf F., Aghajanian C. A., et al. Final results of a phase I study of picoplatin and pegylated liposomal doxorubicin in advanced solid tumor malignancies. J. Clin. Oncol. 2008, 26, 15S (abstract 2568).
254. Karlin D. A., Cheporov S. V., Gladkov O. A., et al. First-line phase Ib and II studies of picoplatin in combination with 5-fluorouracil and leucovorin (FOLPI) as a potential neuropathy-sparing therapy for colorectal cancer (CRC). J. Clin. Oncol. 2008, 2,: 15S (abstract 4100).
255. Karlin D. A., Breitz H., Baker G., et al. A phase 2 study of picoplatin monotherapy for patients with small cell lung cancer (SCLC) who have resistant or refractory disease or have relapsed within 180 days of completing first-line, platinum-containing chemotherapy. J. Thor. Oncol. 2007, 2, Suppl. 4, S424-S425.
256. Perez-Verdia A., Hardwicke F. L., Nugent K. M. Acute cardiac toxicity associated with high-dose intravenous methotrexate therapy: case report and review of the literature. Pharmacotherapy 2005, 25, 1271-1276.
257. Gasser A., Tieche M., Brunner K. Neurologic and cardiac toxicity following IV application of methotrexate. Cancer Treat. Rep. 1982, 66, 1561-1562.
258. Vogelzang N. J., Rusthoven J. J., Symanowski J., et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol. 2003, 21, 2636-2644.
259. Scagliotti G. V., Parikh P., von Pawel J., et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapynaive patients with advanced-stage non-small-cell lung cancer. J. Clin. Oncol. 2008, 26, 3543-3551.
260. Boeck S., Weigand-Kohler K., Fuchs M., et al. Second-line chemotherapy with pemtrexed after gencitabine failure in patients with advanced pancreatic cancer: a multicenter phase II trial. Ann. Oncol. 2008, 18, 745-751.
261. Sonnenblick M., Rosin A. Cardiotoxicity of interferon: a review of 44 cases. Chest 1991, 99, 667-561.
262. Martino S., Ratanatharathom V., Karanes C., et al. Reversible arrhythmias observed in patients treated with recombinant alpha 2 interferon. J. Cancer Res. Clin. Oncol. 1987, 113, 376-378.
263. Cohen M., Huberman M., Nesto R. Recombinant alpha-2 interferon related cardiomyopathy. Am. J. Med. 1988, 85, 549-551.
264. Vial T., Descotes J. Immune-mediated side-effects of cytokines in humans. Toxicology 1995, 105, 2002-2008.
265. Nora R., Abrmas J. S., Tait N. S., et al. Myocardial effects during recombinant interleukin-2 therapy. J. Natl. Cancer Inst. 1989, 81, 59-63.
266. Lee R. E., Lotze M. T., Skibber J. M., et al. Cardiorespiratory effects of immunotherapy with interleukin-2. J. Clin. Oncol. 1989, 7, 7-20.
267. Degrate L., Nobill C., Franciosi C., et al. Interleukin-2 immunotherapy action on innate immunity cells in peripheral-blood and tumoral tissue of pancreatic adenocarcinoma patients. Langenbecks Arch. Surg. 2009, 394, 115-121.
268. Kiladjian J. J., Cassinat B., Chevret S., et al. Pegylated interferon-alpha-2a induces complete hematologic and molecular responses with low toxicity in polycythema vera. Blood 2008, 112, 3065-3072.
269. White R. L., Schwartzentruber D. J., Guleria A., et al. Cardiopulmonary toxicity of treatment with high-dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal cell carcinoma. Cancer 1994, 74, 3212-3222.
270. Wong M. K. K. The current role of immunotherapy for renal cell carcinoma is the era of targeted therapeutics. Curr. Oncol. Rep. 2008, 10, 259-263.
271. King J., Waxman J., Strauss H. Advances in tumor immunotherapy. Quart. J. Med. 2008, 101, 675-683.
272. Tsuruma T., Iwayama Y.,Ohmura T., et al. Clinical and immunological evaluation of anti-apoptosis protein survivan-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancer. J. Tansl. Med. 2008, 6, 24-35.
273. Vonderheide R. H., Domchek S. M., Schultze J. L., et al. Vaccination of cancer patients against telomerase induces functional antitumor CD8{Throw} T lymphocytes. Clin. Cancer Res. 2004, 10, 828-839.
274. Barue M., Bender J., Senzer N., et al. Induction of immune response and clinical efficacy in a phase II trial of IDM-2101, a 20-eitype cytotoxic T-lymphocyte vaccine in metastatic non-small-cell lung cancer, J. Clin. Oncol. 2008, 26, 4418-4425.
275. Press O. W. Evidence mounts for the efficacy of radioimmunotherapy for B-cell lymphomas. J. Clin. Oncol. 2008, 26, 5147-5150.
276. Horning S. J., Younes A., Jain V., et al. Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J. Clin. Oncol. 2005, 23, 712-719.
277. Morschhauser F., Radford J., Van Hoof A., et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J. Clin. Oncol. 2008, 26, 5156-5164.
278. Bross P. F., Beitz J., Chen G., et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin. Cancer Res. 2001, 7, 1490-1496.
279. Amadori S., Suciu S., Stasi R., et al. Gemtuzumab ozogamicin (Mylotarg)as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organization for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto Leukemia Groups. Leukemia 2005, 19, 1768-1773.
280. Sievers E. L., Larson R. A., Stadtmauer E. A., et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J. Clin. Oncol. 2001, 19, 3244-3254.
281. Larson R. A., Sievers E. L., Stadtmauer E. A., et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer 2005, 104, 1442-1452.
282. Roboz G. J., Ritchie E. K., Curcio T., et al. Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia. Cancer 2008, 113, 2504-2511.
283. Tarhini A. A., Kirkwood J. M., Tawbi H., et al. Safety and efficacy of arsenic trioxide for patients with advanced metastatic melanoma. Cancer 2008, 112, 1131-1138.
284. Ohnishi K., Yoshida H., Shigeno K., et al. Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia. Ann. Intern. Med. 2000, 133, 881-886.
285. Wesrervelt P., Brown R. A., Adkins D. R., et al. Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide. Blood 2001, 98, 266-271.
286. Barbey J., Pezzulllo J., Soignet S. Effect of arsenic trioxide on QT interval in patients with advanced malignancies. J. Clin. Oncol. 2003, 21, 3609-3615.
287. Huang C. H., Chen W. J., Wu C. C., et al. Complete atrioventricular block after arsenic trioxide treatment in an acute promyelocytic leukemia patient. Pacing Clin. Electrophysiol. 1999, 22, 965-967.
288. Airey C. L., Dodwell J. K., Jones W. G. Etoposide-related myocardial infarction. Clin. Oncol. 1995, 7, 135-137.
289. Friedberg J. W., Cohen P., Chen L., et al. Bendamustine in patients with rituximabrefractory and alkylator-refractory, indolent, and transformed non-Hodgkin's lymphoma: Results from a phase II multicenter single-agent study. J. Clin. Oncol. 2008, 26, 204-210.
290. Cheson B. J., Rummel M. J. Bendamustine: rebirth of an old drug. J. Clin. Oncol. 2009, 27, 1492-1501.
291. Sakata-Yanagimoto M., Kanda Y., et al. Predictors for severe cardiac complications after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2004, 33, 1043-1047.
292. Murdych T., Weisdorf D. J. Serious cardiac complications during bone marrow transplantation at the University of Minnesota. Bone Marrow Transplant. 2001, 28, 283-287.
293. Hertenstein B., Stefanic M., Schmeister T., et al. Cardiac toxicity of bone marrow transplantation: predictive value of cardiologic evaluation before transplant. J. Clin. Oncol. 1994, 5, 998-1004.
294. Bearman S. I., Petersen F. B., Schor R. A. et al. Radionuclide ejection fractions in the evaluation of patients being considered for bone marrow transplantation: risk for cardiac toxicity. Bone Marrow Transplant. 1990, 5, 173-177.
295. Chung T., Lim W.-C., Cunningham I., et al. subacute cardiac toxicity following autologous haematipoietic stem cell transplantation in patients with normal cardiac function. Heart 2008, 94, 911-918.
296. Cagnoni N. Y., Bearman S. I., Shpall E. J., et al. Cardiac toxicity following high-dose cyclophosphamide, cisplatin, and BCNU (STAMP-1) for breast cancer. Biol. Blood Marrow Transplant. 2000, 6, 198-203.
297. Armenian S. H., Sun C. -L., Francisco F., et al. Late congestive heart failure after hematopoietic cell transplantation. J. Clin. Oncol. 2008, 26, 5537-5543.
298. Baker K. S., Ness K. K., Steinberger J., et al. Diabetes, hypertension, and cardiovascular events in survivors of hematopoietic cell transplantation: a report from the Bone Marrow Transplantation Survivor study. Blood 2007, 109, 1765-1772.
299. Tichelli A., Bucher C., Rovó A., et al. Premature cardiovascular disease after allogeneic hematopoietic stem-cell transplantation. Blood 2007, 110, 3463-3471.
300. Majhail N. S., Flowers M. E., Ness K. K., et al. High prevalence of metabolic syndrome after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2009, 43, 49-54.
301. Tichelli A., Bhatia S., Socie G. Cardiac and cardiovascular consequences after haematopoietic stem cell transplantation. Br. J. Haematol. 2008, 142, 11-26.
302. Tichilli A., Passweg J., Wojcik D., et al. Late cardiovascular events after allogeneic hematopoietic stem cell transplantation: a retrospective multicenter study of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation. Haematologica 2008, 93, 1203-1210.
303. Rackley C., Schultz K. R., Goldman F. D., et al. Cardiac manifestations of graftversus- host disease. Biol. Blood Marrow Transplant. 2005, 11, 773-780.
304. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet 2005, 365, 1687-717.
305. Mouridsen H., Keshaviah A., Coates A. S., et al. Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen safety analysis of BIG 1-98 trial. J. Clin. Oncol. 2007, 25, 5715-5722.
306. Fisher B., Costantino J. P., Wickerham D. L., et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J. Natl. Cancer Inst. 2005, 97, 1652-1662.
307. Hernandez R. K., Sorensen H. T., Jacobsen J., et al. Tamoxifen treatment in Danush breast cancer patients and 5-year risk of arterial atherosclerotic events: a null association. Cancer Epidemiol. Biomarker Rev. 2008, 17, 2509-2511.
308. ATAC Trialists Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005, 365, 60-62.
309. Eisen A., Trudeau M., Shelley W., et al. Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: A systematic review. Cancer Treat. Rev. 2008, 34, 157-174.
310. The ATAC Trialists' Group. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol. 2006, 7, 633-643.
311. Cuzick J., Wale C. A detailed analysis of the benefits of anastrozole over tamoxifen for venous thromboembolic events (VTE) after 5 years' treatment. Breast Cancer Res. Treat. 2006, 100, 104 (abstract).
312. Coombes R. C., Kilburn L. S., Snowdon C. F., et al. Survival and safety of exemestane vs. tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomized controlled trial. Lancet 2007, 369, 559-570.
313. Coates A. S., Keshaviah A., Thurlimann B., et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine- responsive early breast cancer: update of study BIG 1-98. J. Clin. Oncol. 2007, 25, 486-492.
314. Nabholtz J. M. A. Long-term safety of aromatase inhibitors in the treatment of breast cancer. Ther. Clin. Risk Manag. 2008, 4, 189-204.
315. Boccardo F., Rubagotti A., Puntoni M., et al. Switching to anastrozole vs. continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. J. Clin. Oncol. 2005, 23, 5138-5147.
316. Elisaf M. S., Bairaktari E. T., Nicolaides C., et al. Effect of letrozole on the lipid profile in postmenopausal women with breast cancer. Eur. J. Cancer 2001, 37, 1510-1513.
317. Kataja V., Hietanen P., Joensuu H., et al. The effects of adjuvant anastrozole, exemestane, tamoxifen, and toremifene on serum lipid in postmenopausal breast cancer patients - a preliminary study. Eur. J. Cancer 2004, (Suppl. 2), 143.
318. Keefe D. L. The cardiotoxic potential of the 5-HT3 receptor antagonist antiemetics: Is there cause for concern? The Oncologist 2002, 7, 65-72.
319. Navari R. M., Koeller J. M. Electrocardiographic and cardiovascular effects of the 5-hydroxytryptamine3 receptor antagonists. Ann. Pharmacother. 2003, 37, 1276- 1286.
320. De Ponti F., Poluzzi E., Cavalli A., et al. Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes. Drugs 2002, 21, 263-286.
321. Frothingham R., Rates of torsade de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin. Pharmacotherapy 2001, 21, 1468-1472.